Rapport Therapeutics Ratios (2023-2026) | RAPP

Ratios Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter) -99.29%
EBIT Margin (Quarter) -121.08%
EBITDA Margin (Quarter) -104.54%
Operating Margin (Quarter) -121.08%
Net Margin (Quarter) -99.29%
FCF Margin (Quarter) -65.74%
Efficiency
Assets Average (Quarter) 338.62M323.04M308.49M293.77M410.41M523.88M505.01M
Equity Average (Quarter) -11.28M-19.38M-32.63M148.63M330.00M314.27M295.63M274.67M387.56M498.13M478.08M
Invested Capital (Quarter) -9.43M-13.12M-25.63M-39.63M336.89M323.11M305.43M285.84M263.51M511.62M484.65M471.51M
Leverage & Solvency
Equity Ratio (Quarter) -0.160.970.980.970.950.920.960.950.95
Valuation
Enterprise Value (Quarter) -79.53M-159.41M-147.48M-74.37M-110.27M-39.42M-305.28M-57.71M-465.78M-251.46M-52.75M-875.53M
Return Ratios
Return on Sales (Quarter) -0.01%
Return on Capital Employed (Quarter) -22.42%-26.43%-31.12%-36.10%-27.80%-24.78%-25.09%
Return on Assets (Quarter) 0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Return on Equity (Quarter) 0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%